Gilead Sciences, Inc.
Compare market positioning with top industry peers
Explore Gilead Sciences
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$29.4B
Market Cap
$94.5B
Net Income
$8.5B
Employees
18,000
Gilead Sciences is executing a heavily funded strategic pivot toward oncology to offset the inevitable, long-term structural decline of its lucrative HIV monopoly. Under CEO Daniel O'Day, the biopharmaceutical giant generated exactly $27.9 billion in revenue and maintains a $94.5 billion market cap with exactly 18000 employees. The financial narrative in 2026 is defined by aggressive M&A activity; Gilead is utilizing the free cash flow generated by its Biktarvy franchise to fund multi-billion dollar acquisitions of speculative cell therapy and antibody-drug conjugate (ADC) pipelines, desperately attempting to replicate its historic success in virology.
Revenue Trend Analysis
YoY Change
+2.4%
3-Year CAGR
+2.3%
Peak Year
2025
Trend
Mostly Growing
Gilead Sciences, Inc. has reported revenue across 4 fiscal years, compounding at +2.3% annually over 3 years. The most recent year saw a 2.4% increase versus the prior year. Revenue peaked in 2025 at $29.4B. Out of 3 reported periods, 2 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $29.4B | $8.5B | +2.4% |
| FY2024 | $28.8B | — | +6.0% |
| FY2023 | $27.1B | — | -1.4% |
| FY2022 | $27.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Gilead Sciences, Inc. reported approximately $27.9B in fiscal year 2025 with a team of 18,000 employees worldwide.
Gilead Sciences, Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology is driven by steady cash generation and pricing power, enabling Gilead Sciences, Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Gilead Sciences, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/gilead-sciences/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Gilead Sciences, Inc. reported $29B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/gilead-sciences/financials" target="_blank" rel="noopener">CorpDigest — Gilead Sciences, Inc. financials</a></div>